Osteopathies

Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting

Retrieved on:

Monday, August 2, 2021

Musculoskeletal system, Organ systems, Anatomy, Osteopathies, Skeletal system, Aging-associated diseases, Endocrine diseases, Rheumatology, Osteoporosis, Bone density, Bone, Entera

BOSTON and JERUSALEM, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced its poster presentation titled “A Six-month Phase 2 Study of Oral PTH in Postmenopausal Women with Low Bone Mass - An Interim Three-Month Analysis” has been selected by the Program Committee of the American Society for Bone and Mineral Research (ASBMR) for its Annual Meeting scheduled to take place on October 1-4, 2021 in San Diego, California. Dr. Arthur Santora, Entera’s Chief Medical Officer, will present the poster at both the plenary session on October 1 and the general session on October 2, as well as a special session on the Biology of the Aging Skeleton Symposium on September 30.

Key Points:

Three and 6 month results, previously reported by Entera in June 2021 can be found here .
Osteoporosis, characterized by low bone mass and deterioration of bone tissue, can lead to decreased bone strength and increased risk of fracture.
The Companys most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development.
Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.

Medimaps Announces Reimbursement by Center for Medicare and Medicaid Services (CMS) for Trabecular Bone Score for Osteoporosis Fracture Risk Assessment

Retrieved on:

Thursday, July 29, 2021

Health, Technology, Managed care, Software, Radiology, Biotechnology, Musculoskeletal disorders, Musculoskeletal system, Organ systems, Osteopathies, Aging-associated diseases, Endocrine diseases, Rheumatology, Osteonecrosis, Osteoporosis, Bone density, Medication-related osteonecrosis of the jaw, Bone fracture

This is the first new reimbursable CPT code for fracture risk assessment in osteoporosis in almost a decade.

Key Points:

This is the first new reimbursable CPT code for fracture risk assessment in osteoporosis in almost a decade.
The reimbursement amount was released by CMS last week and will become effective and available January 1, 2022.
This is largely a result of the fact that 75% of high-risk patients are not being diagnosed timely4.
Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study, Journal of Bone and Mineral Research.

A Prospective Study in More Than 1,000 Osteoporosis Patients Concluded That Binosto® (Buffered Soluble Alendronate) May Increase Patient Satisfaction, Long-Term Adherence and Therefore Efficacy

Retrieved on:

Tuesday, June 22, 2021

The study enrolled 1,084 postmenopausal women with osteoporosis, newly prescribed Binosto and nave to bisphosphonate therapy.

Key Points:

The study enrolled 1,084 postmenopausal women with osteoporosis, newly prescribed Binosto and nave to bisphosphonate therapy.
At baseline, 31% of enrolled patients reported a medical history of gastrointestinal (GI) tract conditions that did not exclude study participation.
The cumulative incidence of all upper GI AEs related to Binosto observed during the duration of the study was low at 9.6%.
Binosto (Buffered Soluble Alendronate) is a first-line treatment of postmenopausal osteoporosis patients that is associated with preferable pharmacologic properties translating into clinical benefit for patients.

Radius Health Business Update

Retrieved on:

Wednesday, June 2, 2021

Drugs, Organ systems, Medical specialties, Abaloparatide, Aging-associated diseases, Endocrine diseases, Osteopathies, Rheumatology, Progestogens, Osteoporosis, Medroxyprogesterone acetate, Radius

TYMLOS new patient adds in April: modest growth vs. previous 4-month trailing averages

Key Points:

TYMLOS new patient adds in April: modest growth vs. previous 4-month trailing averages
Meaningful FDA guidance on generic peptide requirements published on May 19, 2021
Anticipate abaloparatide depot formulation technical development work to commence 2H, 2021
BOSTON, June 02, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Radius or the Company) (NASDAQ: RDUS), provided a business update covering continued progress for the Company.
Additional business updates will be provided as progress is achieved.
Radius views this new guidance as meaningful in assessing the probability of a generic synthetic peptide being filed and gaining market entry.
Radius lead product, TYMLOS (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Surrozen Publishes Article in Nature Communications Demonstrating Selective Wnt Mimetics Stimulate Bone Mass Accrual in Disease Models of Osteoporosis, Aging and Long-Bone Fracture

Retrieved on:

Tuesday, June 1, 2021

Musculoskeletal system, Medical specialties, Branches of biology, Osteopathies, Aging-associated diseases, Skeletal system, Osteoporosis, Rheumatology, Bone, Medication-related osteonecrosis of the jaw, Antibody

Surrozen designed an antibody-based platform that generates potent and selective Wnt mimetics and uses this platform to engineer bispecific antibodies that specifically target select tissues.

Key Points:

Surrozen designed an antibody-based platform that generates potent and selective Wnt mimetics and uses this platform to engineer bispecific antibodies that specifically target select tissues.
In this paper, the effects of multiple targeted Wnt mimetics, developed through this platform, were evaluated in various disease models of osteoporosis, aging and long-bone fracture to determine the effect on bone repair, bone mass and bone strength.
In these disease models, the Wnt agonists induced rapid and robust bone-building effects and corrected bone-mass deficiency and bone defects.
The results also suggested that combining Wnt mimetics with current clinical treatments for osteoporosis may enhance bone repair and help maintain bone mass.

New Diagnostic Technology Showcased During Osteoporosis Awareness Month

Retrieved on:

Friday, May 14, 2021

Medical specialties, Anatomy, Organ systems, Endocrine diseases, Aging-associated diseases, Osteopathies, Rheumatology, Skeletal system, Osteopenia, Osteoporosis, Bone density, Bone fracture

"The portability and ease of use of REMS technology means screening can begin earlier, better positioning patients and their health care providers to take meaningful steps to prevent the onset of osteoporosis rather than to treat the disease once fractures begin to impact quality of life.

Key Points:

"The portability and ease of use of REMS technology means screening can begin earlier, better positioning patients and their health care providers to take meaningful steps to prevent the onset of osteoporosis rather than to treat the disease once fractures begin to impact quality of life.
"\nMore than half of Americans age 50 and older have a high-risk of bone fracture, making osteoporosis and osteopenia an urgent public health issue.
It is especially prominent in women, as pregnancy and menopause can cause bone density loss.
Portable, diagnostic, radiation-free bone health densitometer - a safe, accurate, and cost-effective medical device elevating bone health awareness and treatment to mainstream medical care.

Global Osteoporosis Markets, Epidemiology and Patient Flow Report 2021 - ResearchAndMarkets.com

Retrieved on:

Friday, May 14, 2021

Health, Pharmaceutical, Medical specialties, Osteopathies, Aging-associated diseases, Organ systems, Health, Endocrine diseases, Rheumatology, Osteoporosis, International Osteoporosis Foundation

b'The "Global Osteoporosis Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Osteoporosis Epidemiology and Patient Flow Analysis - 2021, provides Osteoporosis epidemiology, demographics, and patient flow.

Key Points:

b'The "Global Osteoporosis Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Osteoporosis Epidemiology and Patient Flow Analysis - 2021, provides Osteoporosis epidemiology, demographics, and patient flow.
The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Osteoporosis patients, history of the disease at the population level (Osteoporosis prevalence, Osteoporosis incidence) and at the clinical level (from diagnosis to treated patients).
It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Osteoporosis patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Osteoporosis market sizing, assessing market potential, and developing drug forecast models\nIdentify Osteoporosis patients segments through age groups, gender, and disease sub-types\n'

Susan G. Komen® and American Bone Health™ Unite on Campaign to Empower Women Through Healthy Living

Retrieved on:

Wednesday, May 12, 2021

Women, Oncology, General Health, Health, Philanthropy, Consumer, Fitness & Nutrition, Foundation, Musculoskeletal system, Anatomy, Organ systems, Aging-associated diseases, Osteopathies, Skeletal system, Endocrine diseases, Bone, Bones, Medication-related osteonecrosis of the jaw, Breast cancer

The campaign will target breast cancer survivors, those living with MBC and the general population of women over 45.\n\xe2\x80\x9cWhen it comes to bone health, women need to be their own best advocate.

Key Points:

The campaign will target breast cancer survivors, those living with MBC and the general population of women over 45.\n\xe2\x80\x9cWhen it comes to bone health, women need to be their own best advocate.
This campaign will empower women to take the lead in having a conversation about their bones with their health care providers,\xe2\x80\x9d says Cheryl Hostinak, executive director of American Bone Health.
The campaign will direct participants to the American Bone Health Fracture Risk CalculatorTM to learn about their risk factors.
American Bone Health and American Bone Health Fracture Risk Calculator are trademarks of American Bone Health.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005681/en/\n'

Bone Health Technologies Closes $2.5 Million Funding Round and Appoints New Board Members

Retrieved on:

Monday, May 3, 2021

Musculoskeletal system, Anatomy, Organ systems, Osteopathies, Aging-associated diseases, Endocrine diseases, Rheumatology, Skeletal system, Osteopenia, Osteoporosis, Bone, Medication-related osteonecrosis of the jaw

She brings extensive commercial and technical experience to the board team from a variety of health and medical focused organizations.\nSam Goldberger, MD, MBA brings significant medical expertise to the BHT board.

Key Points:

She brings extensive commercial and technical experience to the board team from a variety of health and medical focused organizations.\nSam Goldberger, MD, MBA brings significant medical expertise to the BHT board.
Dr. Goldberger is Co-Founder and Managing Partner of Ambit Health Ventures and has over 28 years of surgical experience.
Studies have shown that one 30-minute treatment with OsteoBoost reduced bone loss activity in all study participants.\nFor more information on the CEO appointment or Bone Health Technologies and OsteoBoost please visit: http://www.bonehealthtech.com/\nABOUT BONE HEALTH TECHNOLOGIES:Bone Health Technologies is a San Francisco based company that applies science and medical expertise to create better health outcomes for women and men at risk of developing osteoporosis and the associated bone fractures.
Initially created in the med-tech incubator TheraNova, Bone Health Technologies is poised to become the new standard of care in treating both osteoporosis and osteopenia (the precursor to osteoporosis).

National Minority Health Month: The National Osteoporosis Foundation Provides New Resources for Multicultural Audiences

Retrieved on:

Friday, April 30, 2021

Medical specialties, Osteopathies, Organ systems, Aging-associated diseases, Endocrine diseases, Rheumatology, Health, Osteoporosis, Osteology, Royal Osteoporosis Society, World Osteoporosis Day

b'ARLINGTON, Va., April 30, 2021 /PRNewswire/ --April is National Minority Health Month and the National Osteoporosis Foundation wants to continue its contribution to bridging the gap in health disparity by providing awareness and education materials to our underserved minority audiences.

Key Points:

b'ARLINGTON, Va., April 30, 2021 /PRNewswire/ --April is National Minority Health Month and the National Osteoporosis Foundation wants to continue its contribution to bridging the gap in health disparity by providing awareness and education materials to our underserved minority audiences.
"Our hope is that we can make a difference in helping the Spanish-speaking community by providing the information they need to know about bone health.
"\nEstablished in 1984, the National Osteoporosis Foundation is the nation\'s leading health organization dedicated to preventing osteoporosis and broken bones, promoting strong bones for life and reducing human suffering through programs of awareness, education, advocacy and research.
For more information on the National Osteoporosis Foundation, visit www.nof.org .\nView original content to download multimedia: http://www.prnewswire.com/news-releases/national-minority-health-month-t...\n'